FDA ▶ Regulatory submissions

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy (2013)

  Back

https://uploads-ssl.webflow.com/65dc93ef0a9b2f3705d0635e/660290ce4aa2f3744020875d_03_Pfizer_Logo.png

https://www.clinicaltrials.gov/study/NCT01994889

Read also



Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
FDA
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (2019)
READ MORE →
 CardiAMP™ Cell Therapy for Heart Failure Trial (2016)
FDA
CardiAMP™ Cell Therapy for Heart Failure Trial (2016)
READ MORE →
 Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
FDA
Effect of RBT-1 on Reducing the Risk of Post-Operative Complications in Subjects Undergoing Cardiac Surgery (2023)
READ MORE →
 Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (2019)
FDA
Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (2019)
READ MORE →